Intuitive Surgical stock reports an earnings beat as revenue rises

Intuitive Surgical stock traded at USD 400.75 on Nasdaq on September 24, 2026, up USD 2.45 or 0.62 percent during the session. The latest earnings comparison remains the central company-specific figure: Q2 2026 adjusted EPS reached USD 2.80 versus a consensus estimate of USD 2.48.

Revenue rises 18.4 percent

According to MarketBeat, Intuitive Surgical reported Q2 2026 revenue of USD 2.89 billion, up 18.4 percent from the same quarter a year earlier. Revenue also exceeded the USD 2.83 billion consensus estimate by USD 0.06 billion.

The earnings spread was wider than the revenue beat. Adjusted EPS exceeded the USD 2.48 estimate by USD 0.32, while the prior-year quarterly EPS figure cited by MarketBeat was USD 1.81. That places the latest adjusted EPS USD 0.99 above the comparable prior-year figure.

European indication expands use

Simply Wall St reported on September 24, 2026, that Intuitive Surgical received a CE mark for using the da Vinci SP single-port system in transvaginal gynecologic procedures. The additional European indication broadens the system's clinical use and may support recurring instrument, accessory, and service revenue as hospitals adopt the platform.

Intuitive Surgical's investor site identifies the da Vinci surgical system as the company's core product and lists Nasdaq under the ticker ISRG. The business also develops the Ion system for minimally invasive lung biopsy procedures, giving its revenue base a second technology platform beyond robotic surgery.

Stock stays below yearly high

At USD 400.75 on September 24, 2026, the stock stood USD 203.13 below its 52-week high of USD 603.88 and USD 72.18 above its 52-week low of USD 328.57. The gap to the high is 33.64 percent, while the market capitalization was USD 141,576,158,500.

The combination of an 18.4 percent revenue increase, a USD 0.32 adjusted EPS beat and a new European indication gives investors three measurable reference points for assessing Intuitive Surgical's growth profile. The share price remains materially below its yearly high despite the latest earnings outperformance.